Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Crucell focuses on the reasearch & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Currently we are combating twelve major infectious diseases with its range of marketed vaccines in the paediatric, travel and endemic and respiratory fields.
Headquartered in Leiden, The Netherlands, Crucell currently employs more than 1200 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea the United Kingdom and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.
Our vaccine business provides stable and predictable sales and cash flow. We sold more than 100 million vaccine doses in over 80 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel and endemic, and respiratory.
|-||Fully liquid vaccine for protection against five childhood diseases|
|-||Recombinant hepatitis B vaccine|
|-||Vaccine for protection against measles and rubella (all age groups)|
|-||Low dosage unique aluminum-free hepatitis A vaccine (0.25ml)|
Travel and Endemic:
|-||Aluminum-free hepatitis A vaccine|
|-||Oral typhoid vaccine|
|-||Internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera|
Travel and Endemic:
|-||Virosomal adjuvanted influenza (all age groups)|
Crucell has a broad development pipeline, including vaccines and antibody products. Several Crucell products are based on our unique PER.C6® production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are Johnson & Johnson, DSM Biologics, Novartis, sanofi aventis, MedImmune, GSK, CSL, Merck and Wyeth.
For more information, please visit the About Us section.